Agilent Technologies, Inc. logo
Agilent Technologies, Inc. (A)
Compare

Agilent Technologies, Inc. (A) Debt to Equity Ratio: 0.50

Is Agilent Technologies, Inc.’s debt to equity ratio high or low?

Agilent Technologies, Inc.'s debt to equity ratio of 0.50 is in line with its 5-year average of 0.52, near the low end of its 5-year range (0.47–0.61).

As of Thursday, June 11, 2026. 9.91% below its 12-month average of 0.55.

A Debt to Equity Ratio Chart

A Debt to Equity Ratio
0.50-18.03% 1Y
Zoom

A Average Debt to Equity Ratio Chart

A Current vs Average Debt to Equity Ratio Chart

A Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.50

DEBT TO EQUITY RATIO AVG TTM

0.55

DEBT TO EQUITY RATIO AVG 3Y

0.53

DEBT TO EQUITY RATIO AVG 5Y

0.52

DEBT TO EQUITY RATIO AVG 10Y

0.48

DEBT TO EQUITY RATIO AVG 15Y

0.51

DEBT TO EQUITY RATIO AVG 20Y

0.54

CURRENT VS TTM AVG

-9.91%

CURRENT VS 3Y AVG

-4.76%

CURRENT VS 5Y AVG

-2.91%

CURRENT VS 10Y AVG

+4.56%

CURRENT VS 15Y AVG

-2.32%

CURRENT VS 20Y AVG

-6.58%

A Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Agilent Technologies, Inc. (A)$36.21B0.500.550.530.52
Zoetis Inc. (ZTS)$34.27B2.852.131.861.81
Centene Corporation (CNC)$32.26B0.940.840.830.81
Medline Inc. (MDLN)$30.90B1.171.090.790.79
IQVIA Holdings Inc. (IQV)$30.08B2.492.412.342.26
Biogen Inc. (BIIB)$28.94B0.380.390.440.53
DexCom, Inc. (DXCM)$28.92B0.510.871.001.01
IDEXX Laboratories, Inc. (IDXX)$43.84B0.670.651.101.25
Humana Inc. (HUM)$44.54B0.730.740.750.72
Veeva Systems Inc. (VEEV)$26.31B0.010.010.010.02

Financial Health

Debt/Equity

0.50

Current Ratio

1.96

Agilent Technologies, Inc. Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Agilent Technologies, Inc. Debt to Equity Ratio FAQ

What is the debt to equity ratio for Agilent Technologies, Inc. (A)?
The debt to equity ratio for A stock is 0.50.
Is Agilent Technologies, Inc.'s debt to equity ratio high or low?
Agilent Technologies, Inc.'s debt to equity ratio of 0.50 is in line with its 5-year average of 0.52, near the low end of its 5-year range (0.47–0.61).
What is the TTM average debt to equity ratio for Agilent Technologies, Inc. (A)?
The TTM average debt to equity ratio for A stock is 0.55.
What is the 3Y average debt to equity ratio for Agilent Technologies, Inc. (A)?
The 3Y average debt to equity ratio for A stock is 0.53.
What is the 5Y average debt to equity ratio for Agilent Technologies, Inc. (A)?
The 5Y average debt to equity ratio for A stock is 0.52.
What is the 10Y average debt to equity ratio for Agilent Technologies, Inc. (A)?
The 10Y average debt to equity ratio for A stock is 0.48.
What is the 15Y average debt to equity ratio for Agilent Technologies, Inc. (A)?
The 15Y average debt to equity ratio for A stock is 0.51.
What is the 20Y average debt to equity ratio for Agilent Technologies, Inc. (A)?
The 20Y average debt to equity ratio for A stock is 0.54.

Agilent Technologies, Inc. Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2025-10-310.50
2024-10-310.61
2023-10-310.47
2022-10-310.52
2021-10-310.51
2020-10-310.48
2019-10-310.51
2018-10-310.39
2017-10-310.42
2016-10-310.45
2015-10-310.40
2014-10-310.31
2013-10-310.51
2012-10-310.46
2011-10-310.51
2010-10-311.14
2009-10-311.16
2008-10-310.83
2007-10-310.65
2006-10-310.41
2005-10-310.00
2004-10-310.32
2003-10-310.41
2002-10-310.25
2001-10-310.00
2000-10-310.02
1999-10-310.00
1998-10-310.00

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA
17,900 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell